<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038920</url>
  </required_header>
  <id_info>
    <org_study_id>MLN0002/CCT-001</org_study_id>
    <secondary_id>U1111-1150-2688</secondary_id>
    <nct_id>NCT02038920</nct_id>
  </id_info>
  <brief_title>Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease</brief_title>
  <official_title>Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled,
      parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002
      (Vedolizumab) in induction and maintenance therapy in Japanese patients with moderately or
      severely active Crohn's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled,
      parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous
      Vedolizumab (300 mg) infusion in induction and maintenance therapy in Japanese patients with
      moderately or severely active Crohn's disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 28, 2014</start_date>
  <completion_date type="Anticipated">February 21, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction phase: Crohn's Disease Activity Index (CDAI)-100 response at Week 10</measure>
    <time_frame>At Week 10</time_frame>
    <description>Percentage of subjects randomized to the induction phase with a decrease from baseline of at least 100 points in the Crohn's Disease Activity Index (CDAI) score at Week 10CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance Phase: Clinical remission at Week 60</measure>
    <time_frame>At Week 60</time_frame>
    <description>Percentage of subjects randomized to the maintenance phase with clinical remission (Crohn's Disease Activity Index (CDAI) score ≤150) at Week 60 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From baseline to 16 weeks after the last dose of study drug</time_frame>
    <description>Tabulation of incidence of adverse events Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>From baseline to 16 weeks after the last dose of study drug</time_frame>
    <description>Summary statistics for body weight at each evaluation time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From baseline to 16 weeks after the last dose of study drug</time_frame>
    <description>Summary statistics for vital signs at each evaluation time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>From baseline to 16 weeks after the last dose of study drug</time_frame>
    <description>Summary statistics for Electrocardiogram (ECG) measurements at each evaluation time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory test (bloodbiochemistry, hematology, and urinalysis)</measure>
    <time_frame>From baseline to 16 weeks after the last dose of study drug</time_frame>
    <description>Summary statistics for measurements of clinical laboratory test at each evaluation time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction phase: Clinical remission at Week 10</measure>
    <time_frame>At Week 10</time_frame>
    <description>Percentage of subjects randomized to the induction phase with clinical remission (Crohn's Disease Activity Index (CDAI) score ≤150) at Week 10 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction phase: Changes in C-reactive protein (CRP) values</measure>
    <time_frame>From baseline to Week 10</time_frame>
    <description>Summary statistics of C-reactive protein (CRP) values at each evaluation time point in the subpopulation of subjects randomized to the induction phase with a baseline CRP value exceeding 0.30 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Crohn's Disease Activity Index (CDAI)-100 response at Week 60</measure>
    <time_frame>At Week 60</time_frame>
    <description>Percentage of subjects randomized to the maintenance phase with a decrease from baseline of at least 100 points in the Crohn's Disease Activity Index (CDAI) score at Week 60 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Durable clinical remission</measure>
    <time_frame>From Week 14 to Week 60</time_frame>
    <description>Percentage of subjects randomized to the maintenance phase with clinical remission (Crohn's Disease Activity Index (CDAI) score ≤ 150) at at least 80 percent of the scheduled visits, including Week 60 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Corticosteroid-free clinical remission at Week 60</measure>
    <time_frame>At Week 60</time_frame>
    <description>Percentage of subjects randomized to the maintenance phase who are not using the corticosteroids used at initiation of study drug administration and who show clinical remission (Crohn's Disease Activity Index (CDAI) score ≤ 150) at Week 60 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Vedolizumab concentration</measure>
    <time_frame>From Week 2 to Week 60</time_frame>
    <description>Summary statistics for serum Vedolizumab concentration at each evaluation time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human anti-human antibody(HAHA)</measure>
    <time_frame>From baseline to 16 weeks after the last dose of study drug</time_frame>
    <description>Tabulation of incidence of Human anti-human antibody (HAHA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody</measure>
    <time_frame>From baseline to 16 weeks after the last dose of study drug</time_frame>
    <description>Tabulation of incidence of neutralizing antibody</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Vedolizumab 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Vedolizumab (300 mg) administered at Weeks 0, 2, and 6 and every 8 weeks thereafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vedolizumab Placebo. Intravenous infusion at Weeks 0, 2, and 6 and every 8 weeks thereafter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vedolizumab</intervention_name>
    <description>Vedolizumab intravenous injection</description>
    <arm_group_label>Vedolizumab 300mg</arm_group_label>
    <other_name>MLN0002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vedolizumab placebo</intervention_name>
    <description>Vedolizumab placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patients aged 15 to 80 years (inclusive) at the time of consent 2. Patients with a
             diagnosis of small-intestinal, large-intestinal,or small-/large-intestinal Crohn's
             disease established based on the Revised Diagnostic Criteria for Crohn's disease
             issued by Research Group for Intractable Inflammatory Bowel Disease Designated as
             Specified Disease by the Ministry of Health, Labor and Welfare of Japan (2012) at
             least 3 months before the start of administration of study drug 3. Patients with
             baseline Crohn's Disease Activity Index (CDAI) score of 220 to 450(inclusive) and
             meeting at least one of the followings:

               -  C-reactive protein (CRP) at screening test is above 0.30 mg/dL

               -  Patients with irregular or semicircular ulcers or multiple aphthae (10 or more)
                  observed over an extensive area of the small or large intestine on endoscopy or
                  imaging test within the 4 months before the start of administration of study
                  drugs

               -  Patients with longitudinal ulcers or a cobblestone appearance observed in the
                  small or large intestine on endoscopy or imaging test within 4 months before the
                  start of administration of study drugs 4. In case of the patients who meet any of
                  the following criteria; patients with ≥ 8-year history of extensive or limited
                  colitis, patients aged ≥ 50 years, or patients with a first-degree family history
                  of colon cancer, those whom the complication of colon cancer or dysplasia was
                  ruled out by total colonoscopy at the start of study drug administration (Or the
                  results from total colonoscopy performed within 1 year before giving consent are
                  available) 5. Patients meeting the criteria for treatment failure below with at
                  least one of the following agents received within previous 5 year period before
                  giving consent Corticosteroids

               -  Resistance

               -  Dependence

               -  Intolerance Immunomodulators (azathioprine, 6-mercaptopurine or methotrexate)

               -  Refractory

               -  Intolerance Anti-TNFα antibodies

               -  Inadequate response

               -  Loss of response

               -  Intolerance

        Exclusion Criteria:

          -  Patients with an evidence of or suspected abdominal abscess 2. Patients with a history
             of subtotal or total colectomy 3. Patients who have had a resection of the small
             intestine in at least 3 locations or have a diagnosis of short bowel syndrome 4.
             Patients with ileostomy,colostomy,or internal fistula, or severe intestinal stenosis
             5. Patients who started 5-aminosalicylic acid oral drug or probiotics treatment,
             antimicrobials to treat Crohn's disease, or 30 mg/day or less of oral corticosteroids
             within 13 days before initiation of study drug administration. If these drugs were
             used within 14 days before initiation of study drug administration, the dosage must
             have been changed or their use discontinued within 13 days before the initiation of
             study drug administration 6. Patients who have received 5-aminosalicylic acid or
             corticosteroid enemas/suppositories, intravenous corticosteroid injections, or more
             than 30 mg/day of oral corticosteroids, medications for diarrhea-predominant irritable
             bowel syndrome, or Chinese herbal medicine for the treatment of Crohn's disease (e.g.,
             Daikenchuto) within 13 days before initiation of study drug administration 7. Patients
             who have received azathioprine, 6-mercaptopurine, or methotrexate within 27 days
             before initiation of study drug administration. However, this shall not apply to
             patients who have received these drugs for 83 or more days before initiation of the
             study drug administration and continued the steady dose administration of the drugs
             for 27 or more days before initiation of the study drug administration 8. Patients who
             have received cyclosporin, tacrolimus, tofacitinib or any study drugs for treatment of
             ulcerative colitis within 27 days before initiation of the study drug administration
             9. Patients who have received adalimumab within 27 days before initiation of study
             drug administration or any biological drugs other than adalimumab within 55 days
             before initiation of study drug administration.Topical administration (such as
             intraocular implantation for treatment of age-related maculopacy) is allowed 10.
             Patients who have received any live vaccinations within 27 days before initiation of
             study drug administration 11. Patients who have undergone intestinal resection within
             27 days before initiation of study drug administration or those anticipated to require
             intestinal resection during the study 12. Patients who have received leukocytapheresis
             or granulocyte apheresis within 27 days before initiation of the study drug
             administration 13. Patients who have received intravenous hyperalimentation or total
             enteral nutrition within the 20 days before initiation of the study drug
             administration. Or patients who are fasted 14. Patients who have received enteral
             nutrition at &gt; 900 kcal/day or started enteral nutrition at &lt;= 900 kcal/day within the
             20 days before initiation of the study drug administration. Patients receiving 900
             kcal/day or less of enteral nutrition for at least 21 days before initiation of the
             study drug administration whom these dosage was changed or the medications were
             discontinued within 20 days before initiation of the study drug administration 15.
             Patients with evidence of adenomatous colonic polyps that need to be removed at the
             start of study drug administration 16. Patients with a history or an an complication
             of dysplasia of the small or large intestine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyota-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirosaki-shi</city>
        <state>Aomori</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakura-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushino-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasuga-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takasaki-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuyama-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hatsukaichi-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asahikawa-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomakomai-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akashi-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kochi-shi</city>
        <state>Kochi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ohita-shi</city>
        <state>Ohita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriguchi-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga-shi</city>
        <state>Saga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokorozawa-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adachi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakayama-shi</city>
        <state>Wakayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shunan-shi</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kofu-shi</city>
        <state>Yamanashi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

